GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » 14-Day RSI

Mira Pharmaceuticals (Mira Pharmaceuticals) 14-Day RSI : 53.64 (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-26), Mira Pharmaceuticals's 14-Day RSI is 53.64.

The industry rank for Mira Pharmaceuticals's 14-Day RSI or its related term are showing as below:

MIRA's 14-Day RSI is ranked worse than
72.33% of 1142 companies
in the Drug Manufacturers industry
Industry Median: 46.885 vs MIRA: 53.64

Competitive Comparison of Mira Pharmaceuticals's 14-Day RSI

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mira Pharmaceuticals's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's 14-Day RSI falls into.



Mira Pharmaceuticals  (NAS:MIRA) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mira Pharmaceuticals  (NAS:MIRA) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Mira Pharmaceuticals 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Mira Pharmaceuticals (Mira Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.
Executives
Brian Patrick Mcnulty 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff director C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr director, officer: Executive Chairman C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin officer: Pres. & Chief Scientific Off. C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez officer: CFO, Secretary & Treasurer 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll director 100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Erez Aminov director, officer: Chief Executive Officer C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck director C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust 10 percent owner C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173